Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Pituitary

Search In Journal Title:

Abbravation: Pituitary

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1002/prac.18510520153

Search In DOI:

ISSN

1573-7403

Search In ISSN:
Search In Title Of Papers:

Somatostatin receptor ligands in the treatment of

Authors: Monica R Gadelha Luiz Eduardo Wildemberg Marcello D Bronstein Federico Gatto Diego Ferone
Publish Date: 2017/02/07
Volume: 20, Issue: 1, Pages: 100-108
PDF Link

Abstract

Firstgeneration somatostatin receptors ligands SRL are the mainstay in the medical treatment of acromegaly however the percentage of patients controlled with these drugs significantly varies in the different studies Many factors are involved in the resistance to SRL In this review we update the physiology of somatostatin and its receptors sst the use of SRL in the treatment of acromegaly and the factors involved in the response to these drugs The SRL act through interaction with the sst which up to now have been characterized as five subtypes The firstgeneration SRL octreotide and lanreotide are considered sst2 specific and have biochemical response rates varying from 20 to 70 Tumor volume reduction can be found in 36–75 of patients Several factors may determine the response to these drugs such as sst AIP Ecadherin ZAC1 filamin A and βarrestin expression in the somatotropinomas In patients resistant to firstgeneration SRL alternative medical treatment options include SRL high dose regimens SRL in combination with cabergoline or pegvisomant or the use of pasireotide Pasireotide is a nextgeneration SRL with a broader pattern of interaction with sst In the light of the recent increase of treatment options in acromegaly and the deeper knowledge of the determinants of response to the current firstline therapy a shift from a trialanderror treatment to a personalized one could be possibleMRG has received unrestricted research grants and lecture fees from Novartis Ipsen and Pfizer has participated on advisory boards of Novartis and Ionis and is PI in clinical trials by Novartis and Ipsen LEW has no conflicts of interest to declare MDB is speaker for Ipsen and Novartis member of Steering Committees of Chiasma Ipsen and Novartis PI of clinical trials of Ipsen Novartis and Pfizer FG is speaker for Novartis and participated on advisory boards of Novartis AMCo Ltd and IONIS Pharmaceuticals DF is speaker participated on advisory boards and received research grants from Novartis and Ipsen

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. IGF-I assays: current assay methodologies and their limitations
  2. Erratum to: An endoscopic modification of the simultaneous ‘above and below’ approach to large pituitary adenomas
  3. Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States
  4. Primary hypothyroidism presenting as pseudoacromegaly
  5. Sellar meningiomas: an endocrinologic perspective
  6. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment
  7. Pituitary tumor apoplexy in patients with Cushing’s disease: endocrinologic and visual outcomes after transsphenoidal surgery
  8. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas
  9. Sellar and clival plasmacytomas: case series of 5 patients with systematic review of 65 published cases
  10. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission
  11. Sellar plasmacytomas: a concise review
  12. Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study
  13. Two cases of Kallmann syndrome associated with empty sella
  14. Multiple head and neck tumors following treatment for craniopharyngioma
  15. Modulation of VEGF/Flk-1 receptor expression in the rat pituitary GH3 cell line by growth factors
  16. Acromegalic gigantism, physicians and body snatching. Past or present?
  17. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
  18. Adipsic diabetes insipidus in adult patients
  19. Pituitary gland and β-catenin signaling: from ontogeny to oncogenesis
  20. Differential diagnosis of ACTH-dependent hypercortisolism: imaging versus laboratory
  21. A novel variation in the AVP gene resulting in familial neurohypophyseal diabetes insipidus in a large Italian kindred
Search Result: